<!DOCTYPE html><html><head><title>Help for package asaur</title>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
<link href="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/themes/prism.min.css" rel="stylesheet" />
<link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.css">
<script type="text/javascript">
const macros = { "\\R": "\\textsf{R}", "\\code": "\\texttt"};
function processMathHTML() {
    var l = document.getElementsByClassName('reqn');
    for (let e of l) { katex.render(e.textContent, e, { throwOnError: false, macros }); }
    return;
}</script>
<script defer src="https://cdn.jsdelivr.net/npm/katex@0.15.3/dist/katex.min.js"
    onload="processMathHTML();"></script>
<link rel="stylesheet" type="text/css" href="R-nav.css" />
</head><body><div class="container"><nav aria-label="Topic Navigation">
<div class="dropdown-menu">
<h1>Package {asaur}</h1>
<h2>Contents</h2>
<ul class="menu">
<li><a href='#ashkenazi'><p>ashkenazi</p>
</a></li>
<li><a href='#ChanningHouse'>
<p>Channing House Data</p></a></li>
<li><a href='#gastricXelox'><p>gasticXelox</p>
</a></li>
<li><a href='#hepatoCellular'><p>hepatoCellular</p>
</a></li>
<li><a href='#pancreatic'><p>pancreatic</p>
</a></li>
<li><a href='#pancreatic2'><p>pancreatic2</p>
</a></li>
<li><a href='#pharmacoSmoking'><p>pharmacoSmoking</p>
</a></li>
<li><a href='#prostateSurvival'><p>prostateSurvival</p>
</a></li>
</ul>
</div>
<hr>
</nav>
<main>
<table>
<tr>
<td>Type:</td>
<td>Package</td>
</tr>
<tr>
<td>Title:</td>
<td>Data Sets for "Applied Survival Analysis Using R""</td>
</tr>
<tr>
<td>Version:</td>
<td>0.50</td>
</tr>
<tr>
<td>LazyData:</td>
<td>true</td>
</tr>
<tr>
<td>Date:</td>
<td>2016-04-10</td>
</tr>
<tr>
<td>Author:</td>
<td>Dirk F. Moore </td>
</tr>
<tr>
<td>Description:</td>
<td>Data sets are referred to in the text "Applied Survival Analysis Using R"
 by Dirk F. Moore, Springer, 2016, ISBN: 978-3-319-31243-9, &lt;<a href="https://doi.org/10.1007%2F978-3-319-31245-3">doi:10.1007/978-3-319-31245-3</a>&gt;.</td>
</tr>
<tr>
<td>Maintainer:</td>
<td>Dirk F. Moore &lt;dirkfmoore@gmail.com&gt;</td>
</tr>
<tr>
<td>License:</td>
<td><a href="https://creativecommons.org/publicdomain/zero/1.0/legalcode">CC0</a></td>
</tr>
<tr>
<td>Repository:</td>
<td>CRAN</td>
</tr>
<tr>
<td>NeedsCompilation:</td>
<td>no</td>
</tr>
<tr>
<td>Packaged:</td>
<td>2016-04-11 14:18:03 UTC; mooredf</td>
</tr>
<tr>
<td>Date/Publication:</td>
<td>2016-04-12 06:23:05</td>
</tr>
</table>
<hr>
<h2 id='ashkenazi'>ashkenazi

</h2><span id='topic+ashkenazi'></span>

<h3>Description</h3>

<p>This is a random subset of data from the Struewing et al. (1997) study of Ashkenazi
jews and breast cancer. The subset consists of pairs of first-degree female
relatives who are also first degree relatives of a proband.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>data("ashkenazi")</code></pre>


<h3>Format</h3>

<p>A data frame with 3920 observations on the following 4 variables.
</p>

<dl>
<dt><code>famID</code></dt><dd><p>family ID indicator</p>
</dd>
<dt><code>brcancer</code></dt><dd><p>1 if subject had breast cancer, 0 if not</p>
</dd>
<dt><code>age</code></dt><dd><p>Age at onset of breast cancer, or current age if no breast cancer</p>
</dd>
<dt><code>mutant</code></dt><dd><p>1 if first degree relative proband was a BRCA mutation carrier, 0 if not</p>
</dd>
</dl>



<h3>References</h3>

<p>Moore DF, Chatterjee N, Pee D, and Gail MH (2001) Pseudo-likelihood estimates 
of the cumulative risk of an autosomal dominant disease from a kin-cohort 
study. Genetic Epidemiology 20, 210-227.)
</p>
<p>Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, 
Brody LC, and Tucker MA (1997) The risk of cancer associated with specific 
mutations of BRCA1 and BRCA2 among ashkenazi jews. 
New England Journal of Medicine 336, 1401-1408.)
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data(ashkenazi)

</code></pre>

<hr>
<h2 id='ChanningHouse'>
Channing House Data
</h2><span id='topic+ChanningHouse'></span>

<h3>Description</h3>

<p>The <code>ChanningHouse</code> data frame has 457 rows and 5 columns. This is 5 fewer
than the parent channing data frame in the boot package. These 5 were
removed because the exit time was not smaller than the entry time.
</p>
<p>Channing House is a retirement centre in Palo Alto, California. These data were collected between the opening of the house in 1964 until July 1, 1975. In that time 97 men and 365 women passed through the centre. For each of these, their age on entry and also on leaving or death was recorded. A large number of the observations were censored mainly due to the resident being alive on July 1, 1975 when the data was collected. Over the time of the study 130 women and 46 men died at Channing House. Differences between the survival of the sexes, taking age into account, was one of the primary concerns of this study.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>data("ChanningHouse")</code></pre>


<h3>Format</h3>

<p>A data frame with 457 observations on the following 5 variables.
</p>

<dl>
<dt><code>sex</code></dt><dd><p>a factor for the sex of each resident with levels <code>Female</code> <code>Male</code></p>
</dd>
<dt><code>entry</code></dt><dd><p>The residents age (in months) on entry to the center)</p>
</dd>
<dt><code>exit</code></dt><dd><p>The age (in months) of the resident on death, leaving the center or July 1, 1975, whichever event occurred first.)</p>
</dd>
<dt><code>time</code></dt><dd><p>The length of time (in months) that the resident spent at Channing House. (<code>time=exit-entry</code>)))</p>
</dd>
<dt><code>cens</code></dt><dd><p>The indicator of reight censoring. 1 indicates that the resident died at Channing House, 0 indicates that they left the house prior to July 1, 1975 or that they were still alive and living in the center at that date.</p>
</dd>
</dl>



<h3>Source</h3>

<p>The current data were derived from the &quot;channing&quot; data frame in the &quot;boot&quot; package. The original source for the data was
</p>
<p>Hyde, J. (1980) Testing survival with incomplete observations. Biostatistics Casebook. R.G. Miller, B. Efron, B.W. Brown and L.E. Moses (editors), 31-46. John Wiley. 
</p>


<h3>References</h3>

<p>Davison, A.C. and Hinkley, D.V. (1997) Bootstrap Methods and Their Application. Cambridge University Press. 
</p>
<p>Canty, A. and Ripley, B. (2015) boot package.
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data(ChanningHouse)
  </code></pre>

<hr>
<h2 id='gastricXelox'>gasticXelox

</h2><span id='topic+gastricXelox'></span>

<h3>Description</h3>

<p>Data from a Phase II clinical trial of Xeloda and exaliplatin given 
before surgery to advanced gastric cancer patients with para-aortic 
lymph node metastasis.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>data("gastricXelox")</code></pre>


<h3>Format</h3>

<p>A data frame with 48 observations on the following 2 variables.
</p>

<dl>
<dt><code>timeWeeks</code></dt><dd><p>survival time in weeks</p>
</dd>
<dt><code>delta</code></dt><dd><p>1 for death, 0 for censored</p>
</dd>
</dl>



<h3>Details</h3>

<p>The data were extracted from the Kaplan-Meier survival plot.
</p>


<h3>References</h3>

<p>Wang Y, Yu Y-Y, Li W, Feng Y, Hou J, Ji Y, Sun Y-H, Shen K-T, Shen Z-B, Qin X-Y, and Liu T-S.
(2014) A phase II trial of xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy 
followed by surgery for advanced gastric cancer patients with para-aortic 
lymph node metastasis. Cancer Chemotherapy and Pharmacology 73(6), 1155-1161.))
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data(gastricXelox)

</code></pre>

<hr>
<h2 id='hepatoCellular'>hepatoCellular

</h2><span id='topic+hepatoCellular'></span>

<h3>Description</h3>

<p>Overall and recurrence-free survival of patients with hepatocellular carcinoma.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>data("hepatoCellular")</code></pre>


<h3>Format</h3>

<p>A data frame with 227 observations on 48 clinical and biomarker variables
</p>

<dl>
<dt><code>Number</code></dt><dd><p>Patient ID number</p>
</dd>
<dt><code>Age</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>Gender</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>HBsAg</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>Cirrhosis</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>ALT</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>AST</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>AFP</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>Tumorsize</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>Tumordifferentiation</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>Vascularinvasion</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>Tumormultiplicity</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>Capsulation</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>TNM</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>BCLC</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>OS</code></dt><dd><p>Overall survival</p>
</dd>
<dt><code>Death</code></dt><dd><p>1 denotes death, 0 censored</p>
</dd>
<dt><code>RFS</code></dt><dd><p>Recurrence-free survival</p>
</dd>
<dt><code>Recurrence</code></dt><dd><p>1 denotes recurrence, 0 censored</p>
</dd>
<dt><code>CXCL17T</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CXCL17P</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CXCL17N</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD4T</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD4N</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD8T</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD8N</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD20T</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD20N</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD57T</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD57N</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD15T</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD15N</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD68T</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD68N</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD4NR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD8NR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD20NR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD57NR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD15NR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD68NR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD4TR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD8TR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD20TR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD57TR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD15TR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD68TR</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>Ki67</code></dt><dd><p>a numeric vector</p>
</dd>
<dt><code>CD34</code></dt><dd><p>a numeric vector</p>
</dd>
</dl>



<h3>References</h3>

<p>Li L, Yan J, Xu J, Liu C-Q, Zhen Z-J, Chen H-W, Ji Y, Wu Z-P, Hu J-Y, Zheng L, Lau WY (2014) 
Cxcl17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. Plos One 9 (10) e110064.
</p>
<p>Li L, Yan J, Xu J, Liu C-Q, Zhen Z-J, Chen H-W, Ji Y, Wu Z-P, Hu J-Y, Zheng L, Lau WY (2014) 
Cxcl17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma. Dryad Digital Repository
datadryad.org. 
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data(hepatoCellular)

</code></pre>

<hr>
<h2 id='pancreatic'>pancreatic

</h2><span id='topic+pancreatic'></span>

<h3>Description</h3>

<p>Data from a Phase II clinical trial of patients with locally advanced or metastatic pancreatic cancer.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>data("pancreatic")</code></pre>


<h3>Format</h3>

<p>A data frame with 41 observations on the following 4 variables.
</p>

<dl>
<dt><code>stage</code></dt><dd><p>a factor with levels <code>LA</code> (locally advanced) or <code>M</code> (metastatic)</p>
</dd>
<dt><code>onstudy</code></dt><dd><p>date of enrollment into the clinical trial, in month/day/year format</p>
</dd>
<dt><code>progression</code></dt><dd><p>date of progression, in month/day/year format</p>
</dd>
<dt><code>death</code></dt><dd><p>date of death, in month/day/year format</p>
</dd>
</dl>



<h3>Details</h3>

<p>Since all patients in this study have known death dates, there is no censoring.
</p>


<h3>References</h3>

<p>Moss RA, Moore D, Mulcahy MF, Nahum K, Saraiya B, Eddy S, Kleber M, and Poplin EA (2012)
A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. Gastrointestinal Cancer Research 5, 77 - 83.
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data(pancreatic)

</code></pre>

<hr>
<h2 id='pancreatic2'>pancreatic2

</h2><span id='topic+pancreatic2'></span>

<h3>Description</h3>

<p>This is the same data as in 'pancreatic', with overall and progression-free survival calculated. Dates have been removed.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>data("pancreatic2")</code></pre>


<h3>Format</h3>

<p>A data frame with 41 observations on the following 4 variables.
</p>

<dl>
<dt><code>pfs</code></dt><dd><p>Progression-free survival: Time from entry until disease progression. 
If no progression was observed, before death, the time to death is used.</p>
</dd>
<dt><code>os</code></dt><dd><p>Overall survival: Time from entry until death</p>
</dd>
<dt><code>status</code></dt><dd><p>This censoring indicator is 1 for all patients, since all patients died.</p>
</dd>
<dt><code>stage</code></dt><dd><p>a factor with levels <code>LA</code> (locally advanced) or <code>M</code> (metastatic)</p>
</dd>
</dl>



<h3>References</h3>

<p>Moss RA, Moore D, Mulcahy MF, Nahum K, Saraiya B, Eddy S, Kleber M, and Poplin EA (2012)
A multi-institutional phase 2 study of imatinib mesylate and gemcitabine for first-line treatment of advanced pancreatic cancer. Gastrointestinal Cancer Research 5, 77 - 83.
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data(pancreatic2)

</code></pre>

<hr>
<h2 id='pharmacoSmoking'>pharmacoSmoking

</h2><span id='topic+pharmacoSmoking'></span>

<h3>Description</h3>

<p>Randomized trial of triple therapy vs. patch for smoking cessation.
</p>


<h3>Usage</h3>

<pre><code class='language-R'>data("pharmacoSmoking")</code></pre>


<h3>Format</h3>

<p>A data frame with 125 observations on the following 14 variables.
</p>

<dl>
<dt><code>id</code></dt><dd><p>patient ID number</p>
</dd>
<dt><code>ttr</code></dt><dd><p>Time in days until relapse</p>
</dd>
<dt><code>relapse</code></dt><dd><p>Indicator of relapse (return to smoking)</p>
</dd>
<dt><code>grp</code></dt><dd><p>Randomly assigned treatment group with levels <code>combination</code> or <code>patchOnly</code></p>
</dd>
<dt><code>age</code></dt><dd><p>Age in years at time of randomization</p>
</dd>
<dt><code>gender</code></dt><dd><p><code>Female</code> or <code>Male</code></p>
</dd>
<dt><code>race</code></dt><dd> <p><code>black</code>, <code>hispanic</code>, <code>white</code>, or <code>other</code></p>
</dd>
<dt><code>employment</code></dt><dd> <p><code>ft</code> (full-time), <code>pt</code> (part-time), or <code>other</code></p>
</dd>
<dt><code>yearsSmoking</code></dt><dd><p>Number of years the patient had been a smoker</p>
</dd>
<dt><code>levelSmoking</code></dt><dd> <p><code>heavy</code> or <code>light</code></p>
</dd>
<dt><code>ageGroup2</code></dt><dd><p>Age group with levels <code>21-49</code> or <code>50+</code></p>
</dd>
<dt><code>ageGroup4</code></dt><dd><p>Age group with levels <code>21-34</code>, <code>35-49</code>, <code>50-64</code>, or <code>65+</code></p>
</dd>
<dt><code>priorAttempts</code></dt><dd><p>The number of prior attempts to quit smoking</p>
</dd>
<dt><code>longestNoSmoke</code></dt><dd><p>The longest period of time, in days, that the patient has previously gone without smoking</p>
</dd>
</dl>



<h3>Source</h3>

<p>This data is from a clinical trial described in Steinberg et al. (2009)
</p>


<h3>References</h3>

<p>Steinberg, M.B. Greenhaus, S. Schmelzer, A.C. Bover, M.T., Foulds, J., Hoover, D.R., and Carson, J.L. (2009) Triple-combination pharmacotherapy for medically ill smokers: A randomized trial.
Annals of Internal Medicine 150, 447-454.
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data(pharmacoSmoking)

</code></pre>

<hr>
<h2 id='prostateSurvival'>prostateSurvival

</h2><span id='topic+prostateSurvival'></span>

<h3>Description</h3>

<p>This data set contains survival times
for two competing causes: time from prostate cancer
diagnosis to death
from prostate cancer, and time from prostate cancer diagnosis to death from
other causes. The data set also contains information on several risk factors.
The data in this data set are simulated from detailed competing risk survival
curves and counts of numbers of patients per group presented in Lu-Yao et al. (2009).
Thus, the simulated data presented here contain many of the characteristics of
the original SEER-Medicare prostate cancer data used in Lu-Yao et al. (2009).
</p>


<h3>Usage</h3>

<pre><code class='language-R'>data("prostateSurvival")</code></pre>


<h3>Format</h3>

<p>A data frame with 14294 observations on the following 5 variables.
</p>

<dl>
<dt><code>grade</code></dt><dd><p>a factor with levels <code>mode</code> (moderately differentiated) and  <code>poor</code> (poorly differentiated)</p>
</dd>
<dt><code>stage</code></dt><dd><p>a factor with levels <code>T1ab</code> (Stage T1, clinically diagnoseed),
<code>T1c</code> (Stage T1, diagnosed via a PSA test), and  
<code>T2</code> (Stage T2)</p>
</dd>
<dt><code>ageGroup</code></dt><dd><p>a factor with levels <code>66-69</code> <code>70-74</code> <code>75-79</code> <code>80+</code></p>
</dd>
<dt><code>survTime</code></dt><dd><p>time from diagnosis to death or last date known alive</p>
</dd>
<dt><code>status</code></dt><dd><p>a censoring variable, <code>0</code>, (censored),
<code>1</code> (death from prostate cancer), and <code>2</code> (death from other causes) </p>
</dd>
</dl>



<h3>Source</h3>

<p>Lu-Yao, GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao S-L (2009) 
Outcomes of localized prostate cancer following conservative management. Journal of the American
Medical Association 302, 1202 - 1209.) 
</p>


<h3>Examples</h3>

<pre><code class='language-R'>data(prostateSurvival)
</code></pre>

</main>

</div>
<script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/prism.min.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.29.0/components/prism-r.min.js"></script>
</body></html>
